PolyCore Therapeutics Competitors and Similar CompaniesClear all
PolyCore Therapeutics's competitors and similar companies include Sosei Heptares, Travere Therapeutics, Antiva Biosciences and OTR3.
 PolyCore Therapeutics PolyCore Therapeutics is a biopharmaceutical company developing treatments for dyskinesia and cognitive impairment associated with neurodegenerative disorders. |  Travere Therapeutics Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. |  Antiva Biosciences Antiva Biosciences is a biopharmaceutical company which develops therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection. |  OTR3 OTR3 is a biotech company that develops therapeutic agents for skin, mucosa, and corneal complications. | ||
Founding Date | Founding Date 2014 | Founding Date 1990 | Founding Date 2011 | Founding Date 2012 | Founding Date 2005 |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Philadelphia, US HQ | Locations Tokyo, JP HQ Dublin, IE Cambridge, GB London, GB | Locations San Diego, US HQ Dublin, IE | Locations South San Francisco, US HQ Redwood City, US | Locations Paris, FR HQ |
Employees | Employees 1 | Employees 387 | Employees 46293% increase | Employees N/A | Employees 23 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 697 m | Valuation ($) 1.4 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥29.6b (FY, 2025) | Revenue (est.) $490.7m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods ¥7.3b (FY, 2025) | Cost of goods $10.3m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit ¥24b (FY, 2025) | Gross profit $480.4m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income (¥12.5b) (FY, 2025) | Net income ($25.5m) (FY, 2025) | Net income N/A | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 65m | Total funding raised $ 25m | Total funding raised $ 56.4m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Sosei Heptares
HQ
Tokyo, JP
Employees
387
Sosei Heptares is a biopharmaceutical company that specializes in drug development.
View companyTravere Therapeutics
HQ
San Diego, US
Employees
462
Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
View companyAntiva Biosciences
HQ
South San Francisco, US
Antiva Biosciences is a biopharmaceutical company which develops therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection.
View companyOTR3
HQ
Paris, FR
Employees
23
OTR3 is a biotech company that develops therapeutic agents for skin, mucosa, and corneal complications.
View company